ReviewFrontiers in oncology2026
Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy resistance and relapse remain major obstacles in the treatment of lymphoid malignancies. While the cancer stem cell (CSC) hypothesis has long served as a conceptual framework for understanding chemoresistance, evidence for its direct applicability in lymphoid malignancies is still limited. More recently, drug-tolerant persister (DTP) cells have emerged as an important model for exploring resistance mechanisms, offering complementary perspectives beyond the CSC paradigm. In this review, we summarize recent advances in the study of DTP cells in lymphoid malignancies, including their progression to drug-tolerant expanded persister (DTEP) cells. We discuss experimental models and methodological approaches for investigating DTP cells, as well as the underlying mechanisms of persistence and resistance, which encompass gene-regulatory changes, cell surface remodeling, and immune evasion strategies. Finally, we highlight potential therapeutic avenues such as targeting glycosylation-related pathways, exploiting immunotherapeutic glycopeptide targets, and implementing rational combination regimens. By integrating insights from DTP biology, this review aims to broaden current theories to therapy resistance in lymphoid malignancies and inform the development of innovative treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.